SecBot SecBot
6-K ·Filed Mar 26, 2026

KMDA

KAMADA LTD
BULLISH
Impact 7/10
Horizonmonths Processed7mo ago SEC0001213900-26-034342
Notable filing: 6-K
Actionable Insight ▲ Bullish

Traders should monitor ramp-up timing toward full capacity and future EMA approval prospects, which could expand market access. The new center strengthens Kamada’s vertical integration and revenue diversification in the high-demand plasma market.

DirectionBullish
Confidencehigh
Horizonmonths

How the stock moved after the report

⚠ Clustered BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$8.22
T+0 close · Mar 26, 2026 · via day close
Latest settled
−14.48%
T+60 · $7.03
Vs SPY
−28.43%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 26 $8.22entry
  2. T+1 · 8mo ago −0.85%α +0.83% · $8.15
  3. T+5 · 8mo ago +3.04%α +1.41% · $8.47
  4. T+20 · 7mo ago +0.73%α −9.94% · $8.28
  5. T+60 · 5mo ago −14.48%α −28.43% · $7.03
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Kamada Ltd. announced FDA approval of its plasma collection center in San Antonio, Texas, enabling the facility to commence commercial sales of normal source plasma. The center has an annual collection capacity of approximately 50,000 liters and is expected to generate $8 million to $10 million in annual revenue at full capacity, supporting both normal and specialty plasma collection.

Key Facts

  • FDA has approved Kamada's plasma collection center in San Antonio, Texas.
  • The facility has a planned annual collection capacity of ~50,000 liters of plasma.
  • Estimated annual revenue contribution of $8 million to $10 million at full capacity from normal source plasma sales.
  • San Antonio center is anticipated to be one of the largest specialty plasma collection centers in the U.S.
  • Kamada now owns three FDA-approved plasma collection centers in Texas (Beaumont, Houston, San Antonio).
  • Company plans to seek European Medicines Agency (EMA) approval for the San Antonio site.

Financial Impact

Adds $8M to $10M in annual revenue at full capacity, representing a meaningful expansion in Kamada's plasma-derived revenue stream.

revenuecapacityplasma supply

Risk Factors

  • Revenue projections are forward-looking and dependent on achieving full operational capacity.
  • Geopolitical risks in the Middle East may impact operations in Israel.
  • Regulatory delays for EMA approval could limit international expansion.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations

Investment Themes

Documents Analyzed

This report is based on 5 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001213900-26-034342
Document: ea0283431-6k_kamada.htm0001213900-26-034342
Document: 0001213900-26-034342-index-headers.html0001213900-26-034342
Document: 0001213900-26-034342-index.html0001213900-26-034342
Document: 0001213900-26-034342.txt0001213900-26-034342

Track record

25 reports on KMDA

Performance horizon

7 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +16.13% at T+20 after the Aug 12, 2026 report. 9 of 10 went positive at some point.

Filters
  1. Nov 9, 20267d ago 6-K Bullish 6/10 No price data
  2. Nov 9, 20267d ago Press Release Bullish 6/10 Entry $7.71 to $8.11 Now $8.11 +5.19% ▲ +5.19% +6.88% vs SPY
  3. Nov 2, 202614d ago 6-K Neutral 2/10 Entry $7.36 to $7.71 Now $8.11 +10.19% ▲ +4.76% +4.68% vs SPY
  4. Oct 6, 20265w ago 6-K Neutral 4/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
  5. Oct 6, 20265w ago Press Release Bullish 6/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
  6. Oct 5, 20266w ago 6-K Neutral 2/10 Entry $8.11 to $7.69 Now $8.11 −0.00% ▼ −5.18% −5.04% vs SPY
  7. Sep 17, 20268w ago 6-K Bullish 6/10 Entry $8.67 to $8.83 Now $8.11 −6.46% ▲ +1.85% +1.24% vs SPY
  8. Sep 16, 20268w ago EFFECT Neutral 3/10 Entry $8.19 to $8.77 Now $8.11 −0.98% ▲ +7.08% +4.52% vs SPY
  9. Sep 10, 20269w ago 6-K Neutral 2/10 Entry $7.99 to $8.67 Now $8.11 +1.50% ▲ +8.51% +9.01% vs SPY
  10. Sep 3, 202610w ago Press Release Neutral 2/10 Entry $8.54 to $8.31 Now $8.11 −5.04% ▼ −2.69% −1.48% vs SPY
Showing 10 of 25

US Market Status

Market Closed · Opens in 9h 25m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 26, 2026